Li Zhiyang, Wu Xin, Zhao Yanjie, Xiao Yinan, Zhao Yunuo, Zhang Ting, Li Hui, Sha Fushen, Wang Yating, Deng Lei, Ma Xuelei
Department of Biotherapy State Key Laboratory of Biotherapy, West China Hospital Sichuan University Chengdu Sichuan China.
West China Hospital, West China School of Medicine Sichuan University Chengdu Sichuan China.
MedComm (2020). 2021 Mar 11;2(1):60-68. doi: 10.1002/mco2.61. eCollection 2021 Mar.
PD-1/PD-L1 (programmed cell death-1 and programmed death-ligand 1) inhibitors utilization in neoadjuvant therapy has been assessed in tumors. This study focused on the clinical benefits of neoadjuvant anti-PD-1/PD-L1 therapy. A comprehensive search was conducted in electronic databases to identify eligible studies. Major response rate (MRR) and complete response rate (CRR) were pooled in this analysis to assess the efficacy of neoadjuvant anti-PD-1/PD-L1 utilization, all grades and high-grade adverse events (AEs) were pooled to evaluate its safety. Twenty studies were included in this meta-analysis, with 828 patients suffering from different tumors. The pooled CRR of triple-negative breast cancer was 0.569 (95% CI 0.514, 0.624, = 0%) and the pooled MRR of lung cancer was 0.471 (95% CI 0.267, 0.575, = 0%). The most frequent adverse event was fatigue (0.272 95% CI 0.171, 0.402, = 87%), and the most common high-grade adverse event was febrile neutropenia (0.084 95% CI 0.063, 0.112, = 85%). In conclusion, neoadjuvant anti-PD-1/PD-L1 therapy received satisfactory clinical results in these tumors included.
程序性细胞死亡蛋白1（PD-1）/程序性死亡配体1（PD-L1）抑制剂在新辅助治疗中的应用已在多种肿瘤中进行了评估。本研究聚焦于新辅助抗PD-1/PD-L1治疗的临床获益。通过在电子数据库中进行全面检索以识别符合条件的研究。本分析汇总了主要缓解率（MRR）和完全缓解率（CRR）以评估新辅助抗PD-1/PD-L1治疗的疗效，汇总了所有级别和高级别不良事件（AE）以评估其安全性。本荟萃分析纳入了20项研究，共828例患有不同肿瘤的患者。三阴性乳腺癌的汇总CRR为0.569（95%CI 0.514，0.624，I² = 0%），肺癌的汇总MRR为0.471（95%CI 0.267，0.575，I² = 0%）。最常见的不良事件是疲劳（0.272，95%CI 0.171，0.402，I² = 87%），最常见的高级别不良事件是发热性中性粒细胞减少（0.084，95%CI 0.063，0.112，I² = 85%）。总之，新辅助抗PD-1/PD-L1治疗在这些纳入的肿瘤中取得了令人满意的临床结果。
